All News

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

Save

Jack Cush, MD

Nov 04, 2020

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.

Read Article

US Differs from Worldwide Drug Reimbursements

Save

Jack Cush, MD

Nov 02, 2020

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine. US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

Read Article

We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients. Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow https://t.co/1SsL9qLJD3

Links:

Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: M…

k dao KDAO2011 ( View Tweet)

Nov 07, 2020

SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq

Eric Dein ejdein1 ( View Tweet)

Nov 07, 2020

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

Janet Pope Janetbirdope ( View Tweet)

Nov 07, 2020

MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj

Dr. Rachel Tate uptoTate ( View Tweet)

Nov 07, 2020

OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX) Abstr#808 #ACR20 @rheumnow https://t.co/TDmV0EJTp8

Links:

Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthrit…

k dao KDAO2011 ( View Tweet)

Nov 07, 2020

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

sheila RHEUMarampa ( View Tweet)

Nov 07, 2020

Never forget how far we have come in rheumatology therapeutics, in a very short period of time. Some of the original slides that Tiny Maini and Marc Feldmann used. @r_burmester giving the Phillip Hench Lecture #ACR20 @RheumNow https://t.co/YI32BX2iw8

David Liew drdavidliew ( View Tweet)

Nov 07, 2020

Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj

Janet Pope Janetbirdope ( View Tweet)

Nov 07, 2020

FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox

Links:

Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tende…

Dr. Rachel Tate uptoTate ( View Tweet)

Nov 07, 2020

What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93

Links:

https://twitter.com/mdwarrington/status/1324743310758563840

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Nov 07, 2020

Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z

sheila RHEUMarampa ( View Tweet)

Nov 06, 2020

Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J

Robert B Chao, MD doctorRBC ( View Tweet)

Nov 06, 2020

This convinces me! #TNF inhibitors vs #JAKI great debate at #ACR20 https://t.co/Xb8KkmDJ8f

KenWarringtonMD MdWarrington ( View Tweet)

Nov 06, 2020

The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow

Eric Dein ejdein1 ( View Tweet)

Nov 06, 2020

More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX

Eric Dein ejdein1 ( View Tweet)

Nov 06, 2020

Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest

Robert B Chao, MD doctorRBC ( View Tweet)

Nov 06, 2020

Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatDebate @RheumNow

k dao KDAO2011 ( View Tweet)

Nov 06, 2020

Korea National Health databased looked at Fracture rates in RA patients taking TNFis, abatacept, or tocilizumab betw 2002 to 2016. They found no difference in Fx risk related to the biologic taken. https://t.co/W2dWWseXTc

Links: